Journal
DRUG DISCOVERY TODAY
Volume 26, Issue 6, Pages 1473-1481Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2021.02.009
Keywords
-
Categories
Funding
- National Institute of Mental Health [MH-103222]
- UK Engineering and Physical Sciences Research Council [EP/S01778X/1, EP/S030336/1]
- EPSRC [EP/S01778X/1, EP/S030336/1] Funding Source: UKRI
Ask authors/readers for more resources
The kynurenine pathway (KP) is significantly activated in COVID-19 patients, affecting neurological functions and inflammation. Modulating this pathway may help reduce neurological symptoms.
The novel respiratory virus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), emerged during late 2019 and spread rapidly across the world. It is now recognised that the nervous system can be affected in COVID-19, with several studies reporting long-term cognitive problems in patients. The metabolic pathway of tryptophan degradation, known as the kynurenine pathway (KP), is significantly activated in patients with COVID-19. KP metabolites have roles in regulating both inflammatory/immune responses and neurological functions. In this review, we speculate on the effects of KP activation in patients with COVID-19, and how modulation of this pathway might impact inflammation and reduce neurological symptoms.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available